List of Tyvaso Dpi drug patents
Tyvaso Dpi is owned by United Therap.
Tyvaso Dpi contains Treprostinil.
Tyvaso Dpi has a total of 6 drug patents out of which 0 drug patents have expired.
Tyvaso Dpi was authorised for market use on 23 May, 2022.
Tyvaso Dpi is available in powder;inhalation dosage forms.
Tyvaso Dpi can be used as method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device.
The generics of Tyvaso Dpi are possible to be released after 01 April, 2035.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(5 years from now) | |
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10130685 | UNITED THERAP | Diketopiperazine salts for drug delivery and related methods |
Aug, 2025
(2 years from now) | |
| US10716793 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(3 years from now) | |
| US10772883 | UNITED THERAP | Diketopiperazine microparticles with defined specific surface areas |
Jun, 2030
(7 years from now) | |
| US10421729 | UNITED THERAP | Microcrystalline diketopiperazine compositions and methods |
Apr, 2035
(11 years from now) | |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 23 May, 2022
Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device
Dosage: POWDER;INHALATION
TYVASO DPI family patents
50
United States
18
Korea, Republic of
13
Japan
9
China
9
European Union
7
Spain
7
Australia
5
Canada
4
Hong Kong
4
Brazil
4
Israel
4
Mexico
3
Denmark
3
Poland
3
Singapore
3
Hungary
2
Malaysia
1
Russia
1
Argentina
1
Taiwan
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic